Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Although the difference did not reach statistical significance, these findings suggest a potential benefit for combination treatment with lapatinib plus letrozole for patients with ER+/ErbB2− breast cancer who develop tamoxifen resistance early during adjuvant treatment with tamoxifen ( 66 ).

also in 111,027 other papers

These analyses showed a trend toward improved PFS and CBR in the lapatinib plus letrozole arm, compared with the letrozole plus placebo arm, for those patients who had ceased tamoxifen <6 months before study entry (PFS: 8.3 versus 3.1 months, respectively, P = 0.117; CBR: 44 versus 32%, respectively).

also in 53,322 other papers